Summary: New data from Wang and colleagues show that complement C3 suppresses the function of CD8+ tumor-infiltrating T cells by inhibiting IL10 production, and targeting the complement receptors C3aR and C5aR enhances the antitumor activity of immune checkpoint blockade. Their results not only define a new role of complement receptors as T-cell coinhibitory receptors, but also are useful in the development of novel strategies to improve the effectiveness of cancer immunotherapy. Cancer Discov; 6(9); 953–5. ©2016 AACR.
See related article by Wang et al., p. 1022.
- ©2016 American Association for Cancer Research.